Shares of Novo Nordisk (NVO) gained 2.8% on Wednesday likely because the analysts at UBS upgraded the company’s rating from “Neutral” to “Buy.” Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes (T2D) and Wegovy injection for weight management.The company competes with Eli Lilly’s (LLY) Zepbound (tirzepatide) in the obesity market. Although Lilly’s Zepbound outperformed Novo Nordisk’s Wegovy (20.2% compared with 13.7%, respectively) in a we ...